Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardio Diagnostics Holdings (CDIO) Research & Development (2022 - 2025)

Historic Research & Development for Cardio Diagnostics Holdings (CDIO) over the last 4 years, with Q1 2025 value amounting to $2200.0.

  • Cardio Diagnostics Holdings' Research & Development fell 7970.48% to $2200.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $20485.0, marking a year-over-year decrease of 7046.44%. This contributed to the annual value of $29125.0 for FY2024, which is 7993.9% down from last year.
  • As of Q1 2025, Cardio Diagnostics Holdings' Research & Development stood at $2200.0, which was down 7970.48% from $5758.0 recorded in Q4 2024.
  • Over the past 5 years, Cardio Diagnostics Holdings' Research & Development peaked at $86665.0 during Q1 2023, and registered a low of $1130.0 during Q1 2022.
  • Moreover, its 4-year median value for Research & Development was $7280.0 (2024), whereas its average is $16688.8.
  • As far as peak fluctuations go, Cardio Diagnostics Holdings' Research & Development soared by 756946.9% in 2023, and later tumbled by 8749.21% in 2024.
  • Quarter analysis of 4 years shows Cardio Diagnostics Holdings' Research & Development stood at $31087.0 in 2022, then crashed by 75.9% to $7492.0 in 2023, then decreased by 23.14% to $5758.0 in 2024, then crashed by 61.79% to $2200.0 in 2025.
  • Its last three reported values are $2200.0 in Q1 2025, $5758.0 for Q4 2024, and $5247.0 during Q3 2024.